blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2258371

EP2258371 - Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.09.2016
Database last updated on 02.11.2024
Most recent event   Tooltip09.09.2016Application deemed to be withdrawnpublished on 12.10.2016  [2016/41]
Applicant(s)For:BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GB  GR  IE  IT  LI  LU  MC  NL  PT  SE  SK  TR 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
For all designated states
GSF - National Research Institute for Environment and Health, GmbH
Ingolstädter Landstrasse 1
85764 Oberschleissheim / DE
For all designated states
The University of Texas System
Board of Regents 201 W. 7th Street
Austin, TX 78701 / US
[2010/49]
Inventor(s)01 / Donato, Nicholas, J.
815 Sandpiper
Sugar Land, TX 77478 / US
02 / Fabbro, Doriano
Im Lee 54
4144, Arlesheim / CH
03 / Manley, Paul, William
Bruggweg 12
4144, Arlesheim / CH
04 / Mestan, Jürgen
Am Rondell St. Cyr 3
79211 Denzlingen / DE
05 / Warmuth, Markus
584 Via Del Caballo
San Marcos, CA 92078 / US
06 / Hallek, Michael
Brunnenstrasse 40
86938, Schondorf / DE
07 / Talpaz, Moshe
6114 Bankside Drive
Houston, TX 77096 / US
08 / Wu, Ji
6206 Bankside Drive
Houston, TX 77096 / US
 [2011/37]
Former [2010/49]01 / Donato, Nicholas, J.
815 Sandpiper
Sugar Land, TX 77478 / US
02 / Fabbro, Doriano
Im Lee 54
4144, Arlesheim / CH
03 / Manley, Paul, William
Bruggweg 12
4144, Arlesheim / CH
04 / Mestan, Jürgen
Zugmantelstrasse 6
79211, Denzlingen / DE
05 / Warmuth, Markus
584 Via Del Caballo
San Marcos, CA 92078 / US
06 / Hallek, Michael
Brunnenstrasse 40
86938, Schondorf / DE
07 / Talpaz, Moshe
6114 Bankside Drive
Houston, TX 77096 / US
08 / Wu, Ji
6206 Bankside Drive
Houston, TX 77096 / US
Representative(s)Pfister-Fu, Yixin, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
[N/P]
Former [2010/49]Pfister-Fu, Yixin, et al
Novartis Pharma AG Patent Department
CH-4002 Basel / CH
Application number, filing date10175362.209.08.2002
[2010/49]
Priority number, dateUS20010311690P10.08.2001         Original published format: US 311690 P
[2010/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2258371
Date:08.12.2010
Language:EN
[2010/49]
Search report(s)(Supplementary) European search report - dispatched on:EP05.11.2010
ClassificationIPC:A61K31/506, A61K31/519, A61P35/02, A61K35/02
[2010/49]
CPC:
A61K35/02 (EP,US); A61K31/506 (EP,US); A61K31/519 (EP,US);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2010/49]
TitleGerman:Verwendung von c-Src Inhibitoren allein oder in Kombination mit STI571 zur Leukämie Behandlung[2010/49]
English:Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia[2010/49]
French:Utilisation d'inhibiteurs c-Src seuls ou en combinaison avec STI571 pour le traitement de leucemies[2010/49]
Examination procedure08.06.2011Examination requested  [2011/29]
22.09.2011Amendment by applicant (claims and/or description)
31.10.2012Despatch of a communication from the examining division (Time limit: M06)
13.08.2013Reply to a communication from the examining division
25.06.2014Despatch of a communication from the examining division (Time limit: M04)
31.10.2014Reply to a communication from the examining division
09.12.2014Despatch of a communication from the examining division (Time limit: M02)
12.02.2015Reply to a communication from the examining division
21.10.2015Despatch of a communication from the examining division (Time limit: M06)
03.05.2016Application deemed to be withdrawn, date of legal effect  [2016/41]
31.05.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2016/41]
Parent application(s)   TooltipEP02794592.2  / EP1418917
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020794592) is  20.07.2004
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.08.2013Request for further processing filed
13.08.2013Full payment received (date of receipt of payment)
Request granted
27.08.2013Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
22.09.2011Request for further processing filed
22.09.2011Full payment received (date of receipt of payment)
Request granted
28.09.2011Decision despatched
Fees paidRenewal fee
07.01.2011Renewal fee patent year 03
07.01.2011Renewal fee patent year 04
07.01.2011Renewal fee patent year 05
07.01.2011Renewal fee patent year 06
07.01.2011Renewal fee patent year 07
07.01.2011Renewal fee patent year 08
07.01.2011Renewal fee patent year 09
11.08.2011Renewal fee patent year 10
10.08.2012Renewal fee patent year 11
19.08.2013Renewal fee patent year 12
01.09.2014Renewal fee patent year 13
31.08.2015Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XD]WO9610028  (CIBA GEIGY AG [CH], et al) [XD] 5-7,13 * claims 1-14 * * page 6, paragraph l - page 7, line 10 *;
 [XD]WO9716452  (CIBA GEIGY AG [CH], et al) [XD] 5,6,13 * claims 1-16 *;
 [X]  - AMOUI M ET AL, "SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR, PP1, INHIBITS BOTH FCEPSILONRI- AND THY-1-MEDIATED ACTIVATION OF RAT BASOPHILIC LEUKEMIA CELLS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, (199708), vol. 27, no. 8, ISSN 0014-2980, pages 1881 - 1886, XP001105330 [X] 5-7,10-14 * abstract *

DOI:   http://dx.doi.org/10.1002/eji.1830270810
 [I]  - MARLEY S B ET AL, "THE TYROSINE KINASE INHIBITOR STI571, LIKE INTERFERON-ALPHA, PREFERENTIALLY REDUCES THE CAPACITY FOR AMPLIFICATION OF GRANULLOCYTE-MACROPHAGE PROGENITORS FROM PATIENTS WITH CHRONIC MYELOID LEUKEMIA", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, (200005), vol. 28, ISSN 0301-472X, pages 551 - 557, XP002949104 [I] 1-4,8,9,15 * abstract *

DOI:   http://dx.doi.org/10.1016/S0301-472X(00)00142-9
 [I]  - TYLER THIESING J ET AL, "EFFICACY OF STI571, AN ABL TYROSINE KINASE INHIBITOR, IN CONJUNCTION WITH OTHER ANTILEUKEMIC AGENTS AGAINST BCR-ABL-POSITIVECELLS", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, (20001101), vol. 96, no. 9, ISSN 0006-4971, pages 3195 - 3199, XP001035245 [I] 1-4,8,9,15 * abstract *
 [I]  - KANO Y ET AL, "IN VITRO CYTOTOXIC EFFECTS OF A TYROSINE KINASE INHIBITOR STI571 IN COMBINATION WITH COMMONLY USED ANTILEUKEMIC AGENTS", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, (20010401), vol. 97, no. 7, ISSN 0006-4971, pages 1999 - 2007, XP001035243 [I] 1-4,8,9,15 * abstract *

DOI:   http://dx.doi.org/10.1182/blood.V97.7.1999
 [I]  - TOPALY J ET AL, "SYNERGISTIC ACTIVITY OF THE NEW ABL-SPECIFIC TYROSINE KINASE INHIBITOR ST1571 AND CHEMOTHERAPEUTIC DRUGS ON BCR-ABL-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA CELLS", LEUKEMIA, MACMILLAN PRESS LTD, US, (200105), vol. 15, ISSN 0887-6924, pages 342 - 347, XP001039741 [I] 1-4,8,9,15 * abstract *

DOI:   http://dx.doi.org/10.1038/sj.leu.2402041
 [A]  - HANKE J H ET AL, "DISCOVERY OF A NOVEL, POTENT, AND SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (19960112), vol. 271, no. 2, ISSN 0021-9258, pages 695 - 701, XP002051826 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1074/jbc.271.2.695
by applicantWO9610028
 WO9707131
 WO9708193
 WO9716452
 WO9728161
 WO9732879
 WO9749706
 WO9903854
    - R. GAMSE ET AL., J. BONE MINER. RES., (1999), vol. 14, no. 1, page S487
    - T. SCHINDLER; F. SICHERI ET AL., MOLECULAR CELL, (1999), vol. 639, no. 3, page 647
    - J.M. HAMBY ET AL., J. MED. CHEM., (1997), vol. 40, pages 2296 - 2303
    - R.L. PANEK ET AL., J. PHARMACOL. EXP. THER., (1997), vol. 283, pages 1433 - 1444
    - S.R. KLUTCHKO ET AL., J. MED. CHEM., (1998), vol. 41, pages 3276 - 3292
    - BAZZONI, G. ET AL., J. CLIN. INVEST., (1996), vol. 98, no. 2, pages 521 - 528
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.